The isolation and characterization of a human T-cell lymphotropic retrovirus related to human T-cell lymphotropic virus type I (HTLV-I) from cerebrospinal fluid of a Jamaican patient with tropical spastic paraparesis is described. The virus isolate is a typical type C retrovirus as seen by electron microscopy and is related to prototype HTLV-I isolated from patients with adult T-cell leukemia but is not identical to this prototype HTLV-I as seen by restriction enzyme mapping.
Human T-cell lymphotropic virus type I (HTLV-I) has been shown to be the etiological agent of tropical spastic paraparesis (TSP) in several parts of the world. We have compared a strain isolated from the cerebrospinal fluid of a Jamaican TSP patient with a prototype HTLV-I isolated from a patient with adult T-cell leukemia (ATL), by restriction enzyme mapping.
TSP is a neurological disorder characterized by paraparesis and spasticity ofthe lower limbs, which is sometimes associated with posterior column and superficial sensory change. Endemic TSP occurs in diverse geographical regions (1) , and recently IgG antibodies to HTLV-I were found in several Caribbean islands (2) (3) (4) , South America (3, 5, 6) , the Seychelles islands (7) , parts of Africa (8) , and also in patients in the more temperate climate of southern Japan, where an identical syndrome called HTLV-I-associated myelopathy (HAM) has been described (9) .
HTLV-I is a type C retrovirus that is endemic in the Caribbean and southern Japan and has been isolated from patients with ATL in these regions (10, 11) .
MATERIALS AND METHODS
Patient and Source of Tissues. The patient CH is a 66-year-old Jamaican female who was first seen at the University Hospital in 1984, approximately 13 years after onset of the disease. She developed progressive difficulty in walking, stiffness ofthe legs, and back pain. Neurological examination showed positive signs of spastic paraparesis with extensor plantar responses and ankle clonus. There was generalized hyperreflexia, more marked in the lower than the upper limbs, and no cortical, cranial nerve, or sensory deficiencies were present. Routine hematological and biochemical laboratory investigations were carried out and samples of heparanized blood, serum, and cerebrospinal fluid (CSF) were obtained for serological, immunological, and virus-isolation studies. The detection of antibodies to HTLV-I in serum and CSF of this patient was done by ELISA and electrophoretic immunoblot (Western blot) techniques (12) . The densitometric measurements on Western blot strips were done with a Dynatech densitometer.
Coculture of CSF or Peripheral-Blood Mononuclear Cells. CSF removed from the patient was spun to obtain mononuclear cells. The CSF mononuclear cells were suspended in RPMI 1640 medium containing 20%o (vol/vol) fetal calfserum and were cocultivated with peripheral-blood or umbilical-cord-blood mononuclear cells at a concentration of 5 x 105 cells in the presence of 0.1% phytohemagglutinin (PHA), 10%o (vol/vol) interleukin 2, and 5 ,g of hydroxycortisone per ml. After 72 hr the cells were fed with culture medium without PHA and subsequently were fed every 4 days. Fresh PHA-activated lymphocytes were added as needed to maintain the cell count. Virus expression was determined by measuring reverse transcriptase, HTLV-I p19, and HTLV-I p24 production by immunofluorescence; the presence of virus particles was determined by electron microscopy. For coculture with patient's mononuclear cells from peripheral blood, the cells were separated by Ficoll/Hypaque centrifugation and cultured at a concentration of S x 10' cells per ml in the presence of 0.1% PHA in RPMI 1640 medium containing 20%o fetal calf serum, 10% interleukin 2, and 5 ,g of hydroxycortisone per ml. After 3 days the cells were cocultivated with PHA-stimulated peripheral-blood lymphocytes or with PHA-stimulated umbilical-cord-blood mononuclear cells. The cultures were examined for virus expression by measuring reverse transcriptase and viral antigen production by indirect immunofluorescence and by electron microscopy. The virus isolate was finally transmitted into H9 and MOLT-3 cells by cocultivation.
Reverse Transcriptase Assays. Reverse transcriptase assays were carried out as described (13, 14) . Briefly the culture supernatant (5 ml) was treated with 30% (wt/vol) polyethylene glycol and 0.4 M NaCl, allowed to stand overnight at 4°C, and centrifuged to pellet the precipitate. The viral precipitate was suspended in 300 ,ul of buffer containing 50 mM Tris HCl (pH 7.5), 5 mM dithiothreitol, 250 mM KCl, and 0.25% Triton X-100. Reverse transcriptase activity was analyzed in a 50-,ul reaction mixture containing 10 ,u1 of the disrupted virus suspension, 50 mM Tris-HCl (pH 7.8), 5 mM dithiothreitol, 100 mM KCI, 0.01% Triton X-100, 10 ,u1 of dT15-rA, as template-primer, 10 (13, 14) . Assays were done in duplicate.
Immunofluorescence Assays. The percentage of cells expressing HTLV-I p19 and p24 was determined by indirect immunofluorescence analysis on fixed cells with monoclonal or polyclonal antibodies to HTLV-I p19 or p24 as described (13) . Briefly, the cultured cells were plated on toxoplasmosis slides and fixed with methanol/acetone, 1:1 (vol/vol), for 30 min at room temperature. The slides were stored in sealed plastic bags at -20°C until ready for use. HTLV-I p19 monoclonal or HTLV-I p24 rabbit antibodies were added to duplicate wells, incubated at room temperature in a humid chamber for 1 hr, and washed with phosphate-buffered saline containing 0.25% Triton X-100 for 2 hr. The cells were then exposed to fluorescein-labeled goat anti-mouse or anti-rabbit IgG (Capell Laboratories different restriction enzymes, and the digested DNA was electrophoresed on a 0.8% agarose gel, transferred to a nitrocellulose membrane, and hybridized with a radiolabeled HTLV-I probe.
RESULTS AND DISCUSSION
With the detection of HTLV-I-related antibodies in the serum and CSF of patients with TSP (1), attempts have been made to isolate and characterize the virus. Recently, the isolation ofan HTLV-I-like virus from the peripheral-blood lymphocytes of TSP patients has been reported (9, 16, 17) , and, as a result of Southern blot analysis, this virus isolate is considered to be identical to HTLV-I from patients with ATL (18) .
This report presents evidence for the isolation and characterization of an HTLV-I strain from the CSF of a patient from Jamaica. Examination of the peripheral blood of patient CH showed the presence of multinucleated giant cells with lobulated nuclei, which are commonly seen in peripheralblood lymphocytes of patients with ATL (Fig. 1) . The peripheral blood of patient CH showed a preponderance of OKT4' helper/inducer T cells (43%) compared with OKT8' suppressor/cytotoxic T cells (12%). Both serum and CSF of this patient showed the presence of HTLV-I-related antibodies, as seen by ELISA and Western blot analysis (Fig. 2) . Cocultures of CSF mononuclear cells from patient CH with peripheral-blood lymphocytes or umbilical-cord-blood lymphocytes resulted in (i) the expression ofa retrovirus that was characterized by the presence of reverse transcriptase in culture supernatants and (ii) the expression of HTLV-I p19 and p24 antigens as determined by immunofluorescence analysis with monoclonal or polyclonal antibodies to HTLV-I p19 or p24. Electron microscopic examination showed the presence of virus particles typical of type C retroviruses with rounded nucleoid cores as seen in HTLV-I (Fig. 3) .
A comparison of the restriction enzyme maps of this virus isolate with eight restriction enzymes (Fig. 4) shows that, although the restriction maps are similar to those of HTLV-I, they are not identical as seen in the restriction patterns with Pst I, Kpn I, Sma I, and Xba I. These results suggest that there are differences between the prototype HTLV-I from ATL patients and the HTLV-I strain isolated from the CSF of a TSP patient. Further 
